IP Library Granted Patent US 9,072,816
Granted Patent B2
US 9,072,816 · App. 13/573,569 · Granted Jul 7, 2015

Composition for modulating inflammation of cardiovascular tissue

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,072,816
App. No.
13/573,569
Granted
Jul 7, 2015
Kind
B2
Abstract

A composition for reconstruction, replacement or repair of damaged or diseased biological tissue comprising an extracellular matrix (ECM) composition that includes an ECM scaffold component derived from a mammalian source and at least one additional bioactive component selected from the group consisting of a statin and a chitin derivative.

Claims (5)

1. A composition for reducing inflammation of damaged cardiovascular tissue and inducing regeneration of cardiovascular tissue, comprising:

an extracellular matrix (ECM) composition comprising acellular small intestine submucosa (SIS),

and 0.1 μM of an added cerivastatin, said ECM composition further comprising transforming growth factor-β (TGF-β), wherein said cerivastatin is mixed with said ECM composition, wherein a statin-growth factor augmented ECM composition is formed, and wherein, when said statin-growth factor augmented ECM composition is administered to damaged cardiovascular tissue, said statin-growth factor augmented ECM composition inhibits localized expression of proinflammatory chemokine monocyte chemoattractant protein-1 (MCP-1) and proinflammatory receptor C—C chemokine receptor type-2 (CCR2),

whereby, said statin-growth factor augmented ECM composition reduces inflammation of said damaged cardiovascular tissue and induces bioremodeling and regeneration of new cardiovascular tissue.

2. The composition of claim 1 , wherein said ECM composition further comprises an additional growth factor selected from the group consisting of fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF).

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2025
From: CORMATRIX CARDIOVASCULAR, INC.
To: CORVIVO CARDIOVASCULAR, INC.
Reel/Frame 070481/0747 →
RELEASE OF SECURITY INTEREST Recorded Jun 2, 2017
From: MIDCAP FINANCIAL TRUST
To: CORMATRIX CARDIOVASCULAR, INC.
Reel/Frame 042669/0559 →
SECURITY INTEREST Recorded Sep 30, 2015
From: CORMATRIX CARDIOVASCULAR, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 036732/0103 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2012
From: MATHENY, ROBERT G
To: CORMATRIX CARDIOVASCULAR, INC.
Reel/Frame 029473/0123 →